BIOMAT Database Logo BIOMAT Database Logo

Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold. 2011

Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Synthetic Organic and Medicinal Chemistry Laboratory (SOMCL), State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.

A series of thieno[2,3-d]pyrimidines and furo[2,3-d]pyrimidines were synthesized and evaluated for the c-Met inhibition. Thieno[2,3-d]pyrimidine 6b stood out as the most potent showing an IC(50) of 35.7 nM. This compound displayed high inhibitory effect on cell proliferation in BaF3-TPR-Met cells and showed high selectivity for c-Met family against other 14 tested kinases. However, compound 6b was found ineffective in the c-Met-dependent U-87MG human gliobastoma xenograft model that may be relevant to its poor PK profile.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013876 Thiophenes A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur. Thiophene
D014183 Transplantation, Heterologous Transplantation between animals of different species. Xenotransplantation,Heterograft Transplantation,Heterografting,Heterologous Transplantation,Xenograft Transplantation,Xenografting,Transplantation, Heterograft,Transplantation, Xenograft
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
February 2015, Bioorganic & medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
December 2017, Bioorganic & medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
December 2017, European journal of medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
February 2015, Bioorganic & medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
February 2014, Molecules (Basel, Switzerland),
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
April 2016, Bioorganic & medicinal chemistry letters,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of new VEGFR-2 inhibitors and apoptosis inducer-based thieno[2,3-d]pyrimidine.
November 2023, Future medicinal chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
July 2021, Bioorganic chemistry,
Ailing Zhao, and Xin Gao, and Yuanxiang Wang, and Jing Ai, and Ying Wang, and Yi Chen, and Meiyu Geng, and Ao Zhang
Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFRL858R/T790M inhibitors.
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!